22 December 2020

International research led by the Radboudumc shows that a full blood count of COVID-19 patients predicts fairly accurately whether the infection will have a complicated course or not. This makes it easier for healthcare providers to estimate the expected clinical picture. This study, conducted in eleven hospitals, has now been published in the scientific journal eLife.

In patients presenting to hospitals with a COVID-19 infection, full blood count analysis (hemocytometry) are commonly performed at the emergency department and during hospitalization. COVID-19 is accompanied by specific changes in the circulating blood cells that are analyzed by a full blood count. These changes in the blood cells, especially those that can be identified using new techniques, are used to create an algorithm with a predictive value. The developed algorithm appears to predict the course of COVID-19 better than the value of the individual blood cells, as used so far. The reliability increases to 93% after six days.

Predicting disease progression

Using data generated by full blood count measurements, the researchers wanted to know whether it is possible to predict whether a hospitalized COVID-19 patient will become seriously ill and needs treatment at the Intensive Care. For this purpose, they examined the data of 982 adult patients in eleven different hospitals across Europe. And this turned out to be possible: specific changes in the circulating blood cells of COVID-19 patients proved to be of use as indicators whether a serious course of events was expected. New laboratory techniques make it possible to detect whether immune cells in the blood are activated and it turned out that especially these activated cells were more present of COVID-19 patients with a severe course, including during the early course of the disease. In a second study population the researchers were able to confirm the value of the prognostic score.

Cheap and available

Internist-infectiologist and principal investigator André van der Ven of Radboudumc explains: "A full blood count is a fully automated, inexpensive, immediately available measurement and one of the most requested laboratory determinations in the world. Full blood count measurements are also routinely requested from COVID-19 patients who present to the hospital. By using certain techniques, the character of certain blood cells can be better determined and by using these new techniques, we have been able to develop a reliable prognostic score. This score gives a good insight into whether a serious course of events can be expected and can help healthcare professionals to make treatment decisions".

About the study

Publication in eLife: A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study – Joachim Linssen, Anthony Ermens, Marvin Berrevoets, Michela Seghezzi, Giulia Previtali, Simone van der Sar-van der Brugge, Henk Russcher, Annelies Verbon, Judith Gillis, Jürgen Riedl, Eva de Jongh, Jarob Saker, Marion Münster, Imke CA Munnix, Anthonius Dofferhof, Volkher Scharnhorst, Heidi Ammerlaan, Kathleen Deiteren, Stephan JL Bakker, Lucas Joost Van Pelt, Yvette Kluiters-de Hingh, Mathie PG Leers, Andre J van der Ven.

Related news items


Radboud Young Academy safeguards the future of science

21 January 2021

New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.

read more

Increase radio- and immunotherapy efficacy by targeting hypoxia

21 January 2021

In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.

read more

Radiation boost lowers risk of prostate cancer recurrence

21 January 2021

An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.

read more

New research through grants for Radboudumc researchers

14 January 2021

Several researchers at the Radboudumc have received grants to start new studies, including on rare diseases, liver disease and cancer metastases. These are grants from the Dutch Research Council, European Joint Programme on Rare Diseases and the Gastric Liver Disease Foundation.

read more

Should we prepare for a corona-related depression wave? Indira Tendolkar and Eric Ruhé talk about their research projects

13 January 2021

Since the outbreak of the SARS-CoV-2, many of us have been staying at home in order to limit our social interactions, to keep ourselves and others safe from the virus. Yet, there’s also concern about what social distancing and anxiety generated by media reports are doing to people's mental health.

read more

RIMLS online award ceremony proudly presenting the winners

13 January 2021

In this special webinar of the RIMLS New Year Celebration, scientific director René Bindels reviewed 2020 and looked forward to 2021. But more importantly a number of researchers received prizes in the traditional RIMLS awards ceremony. 

read more